ensv
bildspel_850x320_springer

News

E-hälsoförsök kan ge bättre koll på KOL-patienter

Pressmeddelande  •  2015-03-24 15:05 CET

Region Skåne vill utveckla en modell där mobil teknik och Internet blir verktyg för att få bättre koll på KOL-patienters hälsotillstånd och för att undvika onödiga inläggningar på sjukhus.

Lungsjukdomen KOL (Kroniskt obstruktiv lungsjukdom ) är en av de vanligaste folksjukdomarna. Uppskattningsvis en halv miljon svenskar lider av sjukdomen som gradvis förvärras och som kräver många sjukvårdsbesök.

Region Skåne vill ta ny teknik till hjälp för att bättre övervaka KOL-patienters hälsa. Forskning indikerar nämligen att man genom att studera deras värden kan förutse när tillståndet är på väg att förvärras. Region Skåne har genomfört en förstudie, delfinansierad av socialdepartementet, med målsättningen att undersöka olika e-hälsoprojekt för KOL-patienter och att föreslå ett koncept som kan användas i Sverige.

“Patienterna upplever en större trygghet”

I en pilotstudie till den planerade e-hälsotjänsten har en patientgrupp i Lund, under ledning av professor Leif Bjermer, dagligen fått fylla i frågeformulär om hur de mår. En applikation på mobiltelefonen har registrerat deras fysiska aktivitet. Dessa data och resultaten av dagliga andningstester har försöksgruppen sedan på distans från hemmet fört in i en patientportal. Modellen bygger på att sjukhuset övervakar patienternas data. Systemet slår larm om värdena försämras och patienterna behöver personlig kontakt med sjukvården.

– Patienterna upplever en större trygghet när de är övervakade i sin sjukdom och deras livskvalitet ökar om de slipper hamna på sjukhus i onödan. Och sjukvården kan så klart spara stora pengar på att förhindra onödiga sjukhusinläggningar, säger Mats Ekelund, forskningschef i Skånevård Kryh som ansvarar för förstudien.

– Vi ser att den demografiska och ekonomiska utvecklingen kräver ett annat arbetssätt inom hälso- och sjukvården än tidigare. Framtidens sjukvård kommer att vara mer uppkopplad än idag och det kommer ständigt nya mobila tjänster som effektiviserar och förbättrar kvaliteten i vården, men också förenklar för patienten. Det här är en tjänst helt i linje med Region Skånes satsning på mobil vård, säger Ingrid Bengtsson Rijavec, Region Skånes hälso- och sjukvårdsdirektör.

Kan bli modell för hela Sverige

Region Skåne söker nu pengar för att vidareutveckla denna e-hälsotjänst med målsättningen att kunna övervaka KOL-patienter i större skala. I etapp 1 är tanken att bygga upp ett samarbete med ett par vårdcentraler i Skåne som redan är certifierade för att ta emot patienter med lungsjudomar.

Om ett sådant projekt faller väl ut kan det införas i hela Skåne och sedan bli en modell för ett bättre omhändertagande av KOL-patienter även på nationell nivå.

Region Skåne ansvarar för hälso- och sjukvården samt utvecklingen av näringsliv, kommunikationer och kultur i Skåne. Region Skåne har drygt 32 000 anställda och omsätter cirka 40 miljarder kronor (2014).Region Skånes högsta beslutande organ är regionfullmäktige, som väljs av invånarna i Skåne.

 

Linde Healthcare continues to support innovation in advanced respiratory care

Research grants to be awarded at Linde Healthcare REALfund event, 8 September 2014 concurrent with the European Respiratory Society Congress in Munich

Pullach, Germany; 8 September 2014 Linde Healthcare, a global business unit of The Linde Group, today announced the new beneficiaries of its REALfund initiative, a programme supporting ideas and projects with the potential to improve patient outcomes and health economics across the wide field of respiratory medicine.

Selected from more than 30 applications, three grantees of the REALfund will receive a total EUR 210.000 to support their innovative research:

Professor Philipp Latzin MD, PhD, University Children Hospital, Basel, Switzerland is researching how to help transfer double tracer gas single-breath washout, an innovative robust, inexpensive, fast and sensitive diagnostic method for small airway disease, into clinics.

Professor Stefan Mihaicuta, MD, PhD FCCP, V. Babes University of Medicine and Pharmacy, Romania is working on implementation of a new methodology for early diagnosis and continuous patient management of sleep apnoea, based on an e-health system facilitated by complex networks science.

Torbjörn L Möller, CareTelCom AB, Veberöd, Sweden is developing and verifying a predictive algorithmic system for early detection of potentially upcoming exacerbations in patients suffering from chronic obstructive pulmonary disease (COPD).

Dr Christian Wojczewski, Head of Linde Healthcare states: “Linde Healthcare continues to be committed to co-operating with researchers from around the world to support research and innovative developments in the area of respiratory care. The newly awarded REALfund grants span a diverse range of research areas – from the transfer of gas-based diagnostic methods into routine clinics, to new methodology for early diagnosis and patient management of sleep apnea, and a new system for prediction of acute exacerbations in patients suffering from COPD – which, when realised, will help healthcare professionals, support healthcare systems and further improve the quality of care and life for patients.”

Grantees of the REALfund are selected with the help of medical and scientific experts and will be supported in their continued research. Dr Konstantin Fiedler, Head of Innovation and Development at Linde Healthcare states: “The aim of Linde Healthcare’s REALfund initiative is to seek and reward ideas that have real potential to be developed into better respiratory care solutions for patients. We commend all applicants to the fund for their commitment to innovation and idea development in this area of healthcare. The grantees saw the potential in their projects and we at Linde Healthcare are delighted to recognise and reward the ideas that will truly benefit patients.”

The REALfund event and awards ceremony will take place on 8 September 2014 concurrent with the European Respiratory Society (ERS) Congress in Munich, Germany. Further information about the REALfund is available at: www.linde-healthcare-realfund.com

About Linde Healthcare

Linde Healthcare is a globally leading healthcare company specialising along an integrated respiratory care path. Linde Healthcare combines pharmaceutical gases, medical devices, services and clinical care into purposeful solutions for patients and healthcare professionals throughout the care continuum from hospital to home. The company is present in over 60 countries and generated revenue of EUR 3,015 billion in 2013. Its product and service offering encompasses a wide range of product-oriented services such as gas supply and gas therapies, sleep and pain therapies, and patient-centred services. Linde Healthcare focuses on four strategic business segments: Hospital Care, Gas Therapies, Homecare and Care Concepts. Long known for expertise in respiratory homecare, our Homecare competencies cover the full spectrum of services with a focus on patients’ individual needs. In the Care Concepts business segment, REMEO® is Linde Healthcare’s innovative programme for long-term mechanically ventilated patient care, offering an integrated care path that bridges the gap between a hospital’s ICU and a patient’s home.

About The Linde Group

In the 2013 financial year, The Linde Group generated revenue of EUR 16.655 bn, making it the largest gases and engineering company in the world with approximately 63,500 employees working in more than 100 countries worldwide. The strategy of The Linde Group is geared towards long-term profitable growth and focuses on the expansion of its international business with forward-looking products and services. Linde acts responsibly towards its shareholders, business partners, employees, society and the environment – in every one of its business areas, regions and locations across the globe. The company is committed to technologies and products that unite the goals of customer value and sustainable development. For more information, see The Linde Group online at www.linde.com

REALfund grantees project titles:

  • Professor Philipp Latzin MD, PhD – Project title: ‘Clinical application of double tracer gas single-breath washout in children with different lung diseases.’
  • Professor Stefan Mihaicuta, MD, PhD FCCP – Project title: ‘Morpheus: A Screening and Monitoring System for Sleep Apnea Syndrome.
  • Torbjörn L Möller – Project title: ‘Mathematical algorithms for early prediction of increasing probability for soon up-coming exacerbation.’ 

Pressrelease

19 November 2012

Startup company CareTelCom AB based in Lund, Sweden, signs collaborative agreement with pharma company Boehringer Ingelheim International GmbH. The initial step of the collaborative effort aims to test CareTelCom’s methodology and technology, and to expand our knowledge related to the complexity of Chronic Obstructive Pulmonary Disease (COPD).

CareTelCom integrates three main medical information areas: fit for purpose investigational methodology; flexibly designed use of real-time technology and systems; and methodology for analyses for prediction and conditioned recommendation for the individual. The systemic approach enables in depth insight of the interplay between factors dictating the individual’s health, in turn providing conditioned control over life.

CareTelCom has developed a service for continuous monitoring, control and follow-up of patients with chronic diseases, in an initial step chronic pulmonary disease. The backbone of the system is based on a combination of biomedical sensors, smartphones, databases, and proprietary software. CTC-ActiwiseTM is the first commercial application. It is specifically designed to suit patients with COPD. According to WHO (World Health Organization) COPD hits 6-8 % of inhabitants in industrialized countries and is the only disease for which the death rate is still increasing. COPD is strongly related to smoking.

In November, CareTelCom initiates in collaboration with Boehringer Ingelheim, Region Skåne and Lund University the evaluation of CTC-ActiwiseTM in an experimental clinical study. In an overlapping next step the clinical study is expanded to proactively evaluate disease progression and through predictive analyses individualize treatment and care.

Boehringer Ingelheim with head quarters in Ingelheim Germany is a key player in the pharmaceutical industry with unique respiratory compounds. Except for the development of world leading drugs, Boehringer Ingelheim is committed to enhance their products to bring individual quality to patients’ lives.

For further information:

CareTelCom AB
Torbjörn L Möller
Mob.: +46 705 50 37 57
torbjorn.moller@www.caretelcom.se

Latest News

Login

Links

Contact

CareTelCom
Phone:+46 40 48 40 25
+46 705 48 95 18

Fler kontaktuppgifter